Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.

Chinese medical journal - 12 Nov 2020

Zhao Zhi-Mei, Wang Song-Ping, Sun Lei, Ji You-Xin

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 33186133
DOI: 10.1097/CM9.0000000000001184
PMCID: PMC7846480

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.PMID 33186133Read ↗

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.Semantic proximity Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.Semantic proximity Read ↗

Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.Semantic proximity Read ↗

A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancerSemantic proximity Read ↗

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read ↗

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.Semantic proximity Read ↗

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.Semantic proximity Read ↗

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancerSemantic proximity Read ↗

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.